Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

Alliance and Hoechst Marion Roussel terminate LiquiVent agreement

Dec. 10, 1997

FDA advisory committee recommends approval of TOBI

Dec. 9, 1997

Byk Gulden presents new PDE IV inhibitors

Dec. 8, 1997

Plant extract with both antiinflammatory and antihistaminic activity

Dec. 4, 1997

New glucocorticoid from Kissei under development for asthma

Dec. 4, 1997

Takeda's PAF antagonist evaluated in preclinical model of asthma

Dec. 2, 1997

Dual-action compound YM-158 shows potential for asthma

Dec. 1, 1997

Preclinical results reported for Novartis' PDE IV inhibitor

Dec. 1, 1997

New antiasthma compound reported at Japanese congress

Dec. 1, 1997

European approvals for RPR's Nasacort AQ

Nov. 28, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Beone eyes Huahui Health’s trispecific HH-160 with $2B option deal
BioWorld
Beone Medicines Ltd. gained an exclusive option to develop cancer immunotherapy HH-160 worldwide in a deal potentially worth more than $2 billion for Huahui...
Unique trial strategy muddies the ODAC waters for camizestrant
BioWorld
Following a discussion that focused more on a new personalized trial strategy rather than the proposed therapy, the U.S. FDA’s Oncologic Drugs Advisory Committee...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...